Characterization of brain development with neuroimaging in a female mouse model of chemotherapy treatment of acute lymphoblastic leukemia

Kellen Gandy¹², Timothy R. Koscik³⁴, Tyler Alexander⁵, Jeffrey D. Steinberg⁶, Kevin R. Krull¹, Ellen van der Plas³⁷

¹Psychology and Biobehavioral Sciences, St. Jude's Children's Research Hospital, Memphis, TN, USA; ²Department of Humanities and Social Sciences, University of Houston-Downtown, Houston, TX, USA; ³Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA; ⁴Department of Neurology, Arkansas Children's Hospital, Little Rock, AR, USA; ⁵Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA; ⁶Center for In Vivo Imaging and Therapeutics, St. Jude's Children's Research Hospital, Memphis, TN, USA; ⁷Department of Hematology/Oncology, Arkansas Children's Hospital, Little Rock, AR, USA

Contributions: (I) Conception and design: T Alexander, KR Krull; (II) Administrative support: KR Krull; (III) Provision of study materials or patients: KR Krull; (IV) Collection and assembly of data: T Alexander, JD Steinberg; (V) Data analysis and interpretation: K Gandy, TR Koscik, E van der Plas; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Kevin R. Krull, PhD. Chair, Department of Psychology and Biobehavioral Sciences, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Mail Stop 735, Memphis, TN 38105, USA. Email: kevin.krull@stjude.org.

Background: Survivors of pediatric acute lymphoblastic leukemia (ALL) exhibit abnormal neurocognitive outcomes that are possibly due to exposures to neurotoxic chemotherapy agents. This study aimed to determine the feasibility of characterizing long-term neuroanatomical changes with in vivo neuroimaging in a preclinical model of treatment for ALL.

Methods: Female mice (C57BL/6) were randomly assigned to a saline control group (n=10) or a treatment group (n=10) that received intrathecal methotrexate and oral dexamethasone (IT-MTX + DEX). Mice were subsequently scanned three times on a 7T MRI at ages 3, 6, and 12 months (T1, T2, and T3, respectively), which corresponds with human age-equivalents spanning early to late adulthood. Regional brain volumes were automatically segmented, and volume change between timepoints (i.e., T1 to T2; and T2 to T3) were compared between groups (i.e., saline vs. IT-MTX + DEX).

Results: Five mice in the IT-MTX + DEX group, and seven mice in the saline group completed all three scans. Between T1 and T2, volumetric change was significantly different between groups in total gray matter (estimate =2.06, 95% confidence interval (CI): 0.27–3.84), the cerebrum (estimate =1.62, 95% CI: 0.14–3.09), claustrum (estimate =0.06, 95% CI: 0.02–0.09), amygdala (estimate =0.06, 95% CI: 0.03–0.29), and striatum (estimate =0.18, 95% CI: 0.01–0.35), with the IT-MTX + DEX group exhibiting a more robust increase in volume than the saline-treated group. Between T2 and T3, group differences in structural brain development were evident for total white matter (estimate =0.14, 95% CI: -0.27 to -0.01), and the corpus callosum (estimate =0.09, 95% CI: -0.19 to 0.00) and amygdala (estimate =0.05, 95% CI: 0.10 to 0.00). In contrast to the rapid brain growth observed earlier in development (i.e., T1 to T2), the IT-MTX + DEX group exhibited an attenuated increase in volume relative to the saline-treated group between T2 and T3.

Conclusions: The results demonstrate feasibility of modeling pediatric ALL treatment in a preclinical model and highlight the potential of using preclinical neuroimaging models to gain insight into brain development throughout survivorship.

Keywords: Acute lymphoblastic leukemia (ALL); neuroimaging; chemotherapy; brain development

© Translational Pediatrics. All rights reserved. Transl Pediatr 2024;13(3):408-416 | https://dx.doi.org/10.21037/tp-23-458

^ ORCID: Kellen Gandy, 0000-0003-4769-9114; Timothy R. Koscik, 0000-0002-2551-8127; Ellen van der Plas, 0000-0002-7490-6636.
Introduction

Survival rates for childhood acute lymphoblastic leukemia (ALL) exceed 90% on current treatment protocols involving administration of risk-stratified intrathecal methotrexate (IT-MTX), dexamethasone (DEX), and other agents (1). Although treatment-associated neurotoxicity has improved in recent decades, childhood ALL survivors remain vulnerable to neurocognitive impairments that affect quality of life (2,3). Previous work in childhood ALL survivors treated with chemotherapy alone have observed associations between neurocognitive impairment and cumulative exposures to IT-MTX and DEX (4-6). Neuroimaging studies demonstrate widespread reductions in gray matter (GM) and white matter (WM), including the nucleus accumbens, amygdala, cerebellum, thalamus, hippocampus, and corpus callosum (7-9). Plasma MTX concentrations have also been found to be associated with functional brain activity, WM integrity in the frontostriatal tract, and cortical thickness in the dorsolateral prefrontal regions (10). Additionally, survivors who received a greater number of IT-MTX injections exhibited less efficient neural network connectivity relative to survivors who received fewer IT injections (11). Improved understanding of chemotherapy-associated neurotoxicity and progression over time is essential in mitigating risk of neurocognitive impairment.

Patients undergoing chemotherapy receive multiple agents through various modalities which makes it challenging to identify specific mechanisms of neurotoxicity (1). While clinical neuroimaging studies have been instrumental in understanding neurocognitive late effects following ALL therapy, these studies are confounded by uncontrolled patient-related factors such as age at diagnosis, treatment intensity, and other psychosocial attributes. Animal models afford opportunities to test hypotheses regarding the impact of chemotherapy on brain development in a controlled environment, within genetically homogenous species (12).

The majority of animal studies have explored the effects of chemotherapy agents using cell biology (13,14), and have provided evidence that chemotherapy agents such as MTX interfere with neurogenesis, gliogenesis, and myelin fiber integrity. Further, DEX has been associated with the upregulation of pro-inflammatory cytokines and gliosis, particularly in the hippocampus (15). While these studies have provided invaluable information about the mechanisms of chemotherapy-induced neurotoxicity, there are limitations to the generalizability of results obtained from cultured cells.

In vivo neuroimaging in animal models enables repeatable, whole-brain measurements to characterize brain growth trajectories across the lifespan, making it an attractive method to study the long-term impact of chemotherapy treatment on the developing brain (1). Spencer Noakes and colleagues (12) utilized longitudinal neuroimaging to demonstrate that exposure to vincristine in young mice was associated with significant alterations in structural brain growth in several different regions at the human age equivalent of early adulthood (12). Using ex vivo magnetic resonance imaging (MRI), the authors also demonstrated that intra-orbitally administered methotrexate and DEX resulted in neuroanatomical changes relative to saline-treated mice (12). Likewise, Berlin and colleagues used ex vivo diffusion tensor imaging to quantify WM in rats that received MTX via intraperitoneal injection for four weeks. Compared to controls, rats exposed to MTX exhibited lower fractional anisotropy across major WM bundles (16).

However, several knowledge gaps remain to be addressed. First, longitudinal patterns of brain growth following IT-
MTX and DEX have not been investigated in preclinical models, even though these agents have been associated with alterations in brain structure and function in cross-sectional clinical studies (5,6). Second, animal studies typically report on the effects of isolated chemotherapy agents, even though pediatric ALL patients receive combined agents throughout therapy (17). Third, while mode of chemotherapy delivery is an important factor of ALL therapy, preclinical studies typically do not account for method of drug delivery (e.g., CNS-directed or oral administration) which could be associated with differential neurotoxicity (12). The present study sought to take the first step in addressing these issues by determining the feasibility of utilizing in vivo neuroimaging to characterize longitudinal brain changes in mice who received IT-MTX and oral DEX. We present this article in accordance with the ARRIVE reporting checklist (available at https://tp.amegroups.com/article/view/10.21037/tp-23-458/rc).

Methods

A protocol was prepared before the study without registration. Healthy, treatment-naïve C57BL/6 wild-type mice obtained from Jackson Laboratory (Bar Harbor, ME) were used in this study. Mice were housed in groups of 5 and nesting materials were provided as enrichment. Littermates were used to minimize genetic and environmental variability among cage mates. Both treatment and control mice were provided DietGel® Recovery (ClearH2O, INC., Westbrook, ME) during the injection period in addition to suspended food pellets to ensure proper nutrition. All procedures were done in the Animal Resource Center at St. Jude Children’s Research Hospital (Memphis, TN). Injections were performed by trained veterinarian technicians in designated procedure rooms. Experiments were performed under an approved project (ARC #: 652-100632) granted by the St. Jude Children’s Research Hospital Institutional Animal Care and Use Committee, in compliance with national guidelines detailed in the Animal Welfare Act (PHS Assurance ID: D16-00043 [A3077-01]).

Chemotherapy protocol

A summary of the study methods is visualized in Figure 1. Twenty female juvenile mice were randomly assigned to receive chemotherapy and DEX (n=10; IT-MTX + DEX) or saline only (n=10; randomization and experimental procedures performed by T.A.). Following an established mouse model of intrathecal ALL therapy that mimics current childhood ALL treatment (18), intrathecal injections were administered between the L5 and L6 vertebrae at 21 days old [human age equivalent (HAE) =3 years], 28 days old (HAE =4 years), and 35 days old (HAE =5 years) under general anesthesia with 3–4% isoflurane. Pharmaceutical-grade, preservative-free MTX injection USP from Teva Pharmaceuticals. MTX or saline was slowly injected into the spinal column using pre-filled syringes with 29-gauge needles, with a total volume administration of 5–10 µL depending on body weight. The animals were subsequently transferred to a recovery cage for close monitoring before returning to their home cage. The IT-MTX + DEX group received 10 mg/kg MTX, and the control group received saline injections of equivalent volume. Mice in the IT-MTX + DEX group were immediately given oral DEX (4 mg/L) in their drinking water for four weeks; equivalent to 1.33 mg/kg/day according to established mouse models of oral DEX (19). All mice were given antibiotics in their drinking water (e.g., tetracycline: 1 g/L; sulfamethoxazole: 600 mg/L; trimethoprim: 102 mg/L) to prevent infections from the DEX-induced immune suppression.

Neuroimaging

Neuroimaging was completed using a 7T Bruker ClinScan small animal MRI system (Bruker Biospin MRI GmbH, Ettlingen, Germany) at the Center for In Vivo Imaging and Therapeutics, which is equipped with an integrated animal handling system with positioner, heating system, anesthesia, and respiratory monitoring apparatus. Temperature, respiration, and heart rate were monitored throughout the scanning session. The system was equipped with four digital receiver channels allowing the operation of multi-channel coils to enhance signaling. Images were acquired with a 4-channel radio frequency (RF) receive-only surface coil placed directly on top of the head and placed inside the magnet within a circularly polarized (CP) whole body RF coil. Mice were sedated with 2-3% isoflurane administered via a nose cone. The neuroimaging acquisition took approximately 10 minutes to complete. All mice were scanned at 3 (T1), 6 (T2), and 12 months (T3) post-treatment (approximate HAE = 23, 34, and 58 years, respectively) (20). At each timepoint, multiple, anisotropic T2-weighted (T2w) images were each acquired in a different acquisition plane specified in Table S1.

Each multiplanar acquisition was first reoriented to a
consistent right-to-left, posterior-to-anterior, inferior-to-superior (RPI) orientation before being rigidly aligned to a mouse brain template (21) and resampled to 70 micron isotropic resolution using a cubic spline interpolation. An initial brain mask was translated to each image by calculating an affine registration to the atlas template. Each acquisition was then denoised, intensity inhomogeneity was corrected, and voxel intensities were rescaled setting the maximum in-brain value to 3,000. Multiplanar images were combined using an iterative template building procedure, where acquisitions were averaged and co-registered iteratively. Using the average T2w image per mouse, the same iterative template building procedure was used to construct a study-specific template. The study-specific template was co-registered using a rigid, affine, and symmetric normalization procedure to the standard atlas. Each mouse underwent a final high-fidelity, non-linear registration to the study template. Transformations were applied in a single interpolation. Jacobian determinants were calculated for the deformation matrix, excluding rigid components, to visualize voxel-wise transformations. A priori brain regions were selected based on the literature, and included: total GM, total WM, cerebrum, cerebellum, corpus callosum, claustrum, amygdala, striatum, thalamus, hypothalamus, hippocampus, and amygdala. These procedures were conducted in a blinded fashion to treatment status of mice.

**Statistical analysis**

Mice that were alive for at least one scanning timepoint were included in the analyses. Raw data were plotted for each observation to inspect distribution. For each region-of-interest (ROI), change in brain volume was calculated between three consecutive timepoints. The differences in the time intervals between scans (3-, 6-, and 12 months) was accounted for by calculating the volume change and dividing the value by the duration between scans. Volume change was assessed at age 6 months (i.e., T1 to T2) and at 12 months (i.e., T2 to T3). Linear models included ROI volume change.
as dependent variables and group (i.e., saline vs. IT-MTX + DEX) as the independent variable. Analyses were conducted in R version 4.2.1, and statistical tests were two-sided.

**Results**

Of the 20 mice included in the study, five mice in the IT-MTX + DEX group died prior to scanning as a result of the injection procedure. Three mice in the saline group died prior to the final scan.

*Figure 2* visualizes the findings across ROIs, and *Tables 1,2* list the group estimates for volume change at 6 months (T1 to T2) and at 12 months (T2 to T3), respectively. Regional volume change between T1 and T2 was significantly different between groups for total GM [estimate =2.06, 95% confidence interval (CI): 0.27–3.84], the cerebrum (estimate =1.62, 95% CI: 0.14–3.09), claustrum (estimate =0.06, 95% CI: 0.02–0.09), amygdala (estimate =0.16, 95% CI: 0.03–0.29), and striatum (estimate =0.18, 95% CI: 0.01–0.35). For each of these regions, the IT-MTX + DEX group exhibited more robust growth than the saline group. As evidenced by the positive estimates in *Table 1*, this pattern was consistent across all ROIs.

Volumes continued to increase between T2 and T3 across groups; however, growth was significantly less robust in the IT-MTX + DEX compared to the saline group for total WM (estimate =−0.14, 95% CI: −0.27 to −0.01). Likewise, growth in the corpus callosum (estimate =−0.09, 95% CI: −0.19 to 0.00) and amygdala (estimate =−0.05, 95% CI: −0.10 to 0.00) was attenuated in the IT-MTX + DEX group compared with the saline group. Group estimates were mostly negative between T2 and T3, suggesting a
Table 1 Group estimates for volumetric change between T1 and T2

<table>
<thead>
<tr>
<th>ROI</th>
<th>Group estimate</th>
<th>95% CI</th>
<th>t(df)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total GM</td>
<td>2.06</td>
<td>0.27 to 3.84</td>
<td>t(13)=2.49</td>
<td>0.03</td>
</tr>
<tr>
<td>Total WM</td>
<td>0.10</td>
<td>-0.34 to 0.54</td>
<td>t(13)=0.49</td>
<td>0.63</td>
</tr>
<tr>
<td>Cerebrum</td>
<td>1.62</td>
<td>0.14 to 3.09</td>
<td>t(13)=2.36</td>
<td>0.03</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>0.18</td>
<td>-0.03 to 0.38</td>
<td>t(13)=1.89</td>
<td>0.08</td>
</tr>
<tr>
<td>Corpus Callosum</td>
<td>0.06</td>
<td>-0.23 to 0.35</td>
<td>t(13)=0.42</td>
<td>0.68</td>
</tr>
<tr>
<td>Claustrum</td>
<td>0.06</td>
<td>0.02 to 0.09</td>
<td>t(13)=3.08</td>
<td>0.009</td>
</tr>
<tr>
<td>Striatum</td>
<td>0.18</td>
<td>0.01 to 0.35</td>
<td>t(13)=2.25</td>
<td>0.04</td>
</tr>
<tr>
<td>Thalamus</td>
<td>0.11</td>
<td>-0.04 to 0.25</td>
<td>t(13)=1.59</td>
<td>0.14</td>
</tr>
<tr>
<td>Hypothalamus</td>
<td>0.07</td>
<td>-0.06 to 0.20</td>
<td>t(13)=1.13</td>
<td>0.28</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>0.08</td>
<td>-0.12 to 0.29</td>
<td>t(13)=0.90</td>
<td>0.39</td>
</tr>
<tr>
<td>Amygdala</td>
<td>0.16</td>
<td>0.03 to 0.29</td>
<td>t(13)=2.74</td>
<td>0.02</td>
</tr>
</tbody>
</table>

Bold values highlight P<0.05. ROI, region of interest; GM, gray matter; WM, white matter; CI, confidence interval.

Table 2 Group estimates for volumetric change between T2 and T3

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group estimate</th>
<th>95% CI</th>
<th>t(df)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total GM</td>
<td>-0.08</td>
<td>-0.97 to 0.82</td>
<td>t(10)=−0.19</td>
<td>0.85</td>
</tr>
<tr>
<td>Total WM</td>
<td>-0.14</td>
<td>-0.27 to -0.01</td>
<td>t(10)=−2.38</td>
<td>0.04</td>
</tr>
<tr>
<td>Cerebrum</td>
<td>0.06</td>
<td>-0.66 to 0.78</td>
<td>t(10)=0.19</td>
<td>0.86</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>-0.10</td>
<td>-0.35 to 0.15</td>
<td>t(10)=−0.89</td>
<td>0.40</td>
</tr>
<tr>
<td>Corpus Callosum</td>
<td>-0.09</td>
<td>-0.19 to 0.00</td>
<td>t(10)=−2.20</td>
<td>0.05</td>
</tr>
<tr>
<td>Claustrum</td>
<td>-0.01</td>
<td>-0.03 to 0.02</td>
<td>t(10)=−0.56</td>
<td>0.59</td>
</tr>
<tr>
<td>Striatum</td>
<td>-0.03</td>
<td>-0.11 to 0.05</td>
<td>t(10)=−0.76</td>
<td>0.47</td>
</tr>
<tr>
<td>Thalamus</td>
<td>-0.02</td>
<td>-0.13 to 0.08</td>
<td>t(10)=−0.47</td>
<td>0.65</td>
</tr>
<tr>
<td>Hypothalamus</td>
<td>-0.02</td>
<td>-0.08 to 0.05</td>
<td>t(10)=−0.56</td>
<td>0.59</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>0.04</td>
<td>-0.01 to 0.09</td>
<td>t(10)=1.77</td>
<td>0.11</td>
</tr>
<tr>
<td>Amygdala</td>
<td>-0.05</td>
<td>-0.10 to 0.00</td>
<td>t(10)=−2.21</td>
<td>0.05</td>
</tr>
</tbody>
</table>

Bold value highlights P<0.05 and italicized values highlights P=0.05 when rounded (the values are 0.052 and 0.051). ROI, region of interest; GM, gray matter; WM, white matter; CI, confidence interval.

Similar patterns across ROIs.

**Discussion**

This study demonstrated proof of concept for assessing the long-term effects of IT-MTX and oral DEX with neuroimaging in a mouse model of childhood ALL therapy. A systematic review of the neuroimaging literature in pediatric ALL survivors treated with chemotherapy reported that the majority of studies have been cross-sectional and conducted during adolescence or young adulthood (7). Neurodevelopment is a dynamic process with continuous change (22,23). Therefore, it is essential to evaluate trajectories of change across the lifespan to better characterize brain development following chemotherapy. However, longitudinal studies in humans can be costly, time consuming, and challenging due to attrition and uncontrollable human factors that may impact research.
outcomes. While caution is warranted when comparing outcomes between species, supplementing human observations with experiments in mice is a critical step to elucidate mechanisms of treatment-related neurocognitive late effects. Pending replication, our results imply that exposure to IT-MTX + DEX during early development may be associated with alterations in brain developmental trajectories throughout the lifespan.

While others have investigated the impact of isolated chemotherapy agents on the mouse brain using neuroimaging (12), longitudinal brain patterns have not been reported for MTX and DEX. In the present study, we demonstrated that IT-MTX + DEX exposed mice initially exhibited more robust growth in regional brain volume relative to saline-treated mice. As demonstrated by literature in children with autism spectrum disorder (24), increased growth rate, or hyper-expansion, does not necessarily reflect improved brain function. Mechanisms of hyper-expansion remain to be fully elucidated, particularly in the context of chemotherapy exposures. However, reactive gliosis following insults to the CNS is known to trigger proliferation and hypertrophy of various glial cells (25). Moreover, repeated exposure to CNS-directed MTX can disrupt reactive glial function and inhibit neuroplasticity (25,26). Interestingly, intraperitoneally injected DEX did not ameliorate gliosis in a mouse model of neurodegeneration (27).

The initial period of potential hyper-expansion was followed by attenuated growth in the chemotherapy-exposed group, particularly in WM. The mouse brain continues to increase in volume throughout late adulthood (28); thus, the observed attenuation of growth later in life in the chemotherapy-exposed mice may reflect accelerated aging (29). Prevalence of frailty among young adult childhood cancer survivors is similar to that of aging adults (30), and it has been hypothesized that childhood cancer and its treatment may cause a shift in the normal aging trajectory (29). MTX and DEX have been demonstrated to cause neuronal and glial injury (26), and the CNS may initially attempt to repair and/or cope with the neurotoxic effects of these agents. However, these coping mechanisms may become less effective with increased age. Consistent with the notion of neural coping, fMRI results in childhood ALL survivors have indicated that the brain may require additional resources to support neurocognitive functions (31). Our knowledge of longitudinal brain changes in aging childhood cancer survivors is limited. At minimum, the results from the current study may help generate hypotheses about aging trajectories in survivors.

Certain limitations of the study warrant consideration. First, the sample included few mice and replication is required prior to making firm conclusions about changes in brain growth in response to IT-MTX + DEX. Second, behavioral data were not collected and as such, the functional consequences of the observed patterns of growth were not evaluated. A behavioral study in rats demonstrated that combined therapies—encompassing cranial radiation, MTX, and prednisone—caused behavioral deficits. Moreover, prednisone appeared to enhance the adverse impact of MTX and radiation (32). More recent work by Wen and colleagues showed that longitudinal exposures to systemic and IT MTX resulted in persistent cognitive deficits in rats (33). Third, while experiments were designed to mimic the clinical experience, treatment exposures in mice were compressed into a timeframe spanning a few weeks. The short lifespan of mice necessitates time compression and affords opportunities for efficient longitudinal assessment; however, the experimental protocol does not fully reflect the extent, intensity, and phasing of ALL therapy. Relatedly, patients with ALL require a variety of agents beyond MTX and DEX, some of which have been shown to have neurotoxic properties (e.g., vincristine) (12). Fourth, observations were limited to female mice, hence, our results are not necessarily generalizable to males. As shown in a growing number of clinical (2,34) and animal studies (33), sex is an important consideration when evaluating neurocognitive development in the context of chemotherapy exposures.

Conclusions

The present study illustrates the potential benefit of leveraging neuroimaging in mouse models of cancer therapy. The results imply that IT-MTX + DEX chemotherapy exposures affect longitudinal brain developmental changes. Our knowledge of chemotherapy-associated brain changes remains limited, and transdisciplinary efforts are required to gain insight into strategies to prevent and/or mitigate neurocognitive late effects associated with pediatric ALL.

Acknowledgments

Funding: This work was supported by the National Cancer Institute at the National Institutes of Health T32 Institutional Research Training Grant (No. T32 CA225590 to K.R.K.), and National Institute of Mental Health (No. MH085849 to K.R.K.).
Footnote

Reporting Checklist: The authors have completed the ARRIVE reporting checklist. Available at https://tp.amegroups.com/article/view/10.21037/tp-23-458/rc

Peer Review File: Available at https://tp.amegroups.com/article/view/10.21037/tp-23-458/prf

Data Sharing Statement: Available at https://tp.amegroups.com/article/view/10.21037/tp-23-458/dss

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-23-458/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Experiments were performed under an approved project (ARC #: 652-100632) granted by the St. Jude Children’s Research Hospital Institutional Animal Care and Use Committee, in compliance with national guidelines detailed in the Animal Welfare Act (PHS Assurance ID: D16-00043 [A3077-01]).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/

References


<table>
<thead>
<tr>
<th>Anatomical acquisition plane</th>
<th>Variable</th>
<th>Acquisition parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Axial</td>
<td>TE, ms</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>TR, s</td>
<td>2.38</td>
</tr>
<tr>
<td></td>
<td>Matrix</td>
<td>256×256</td>
</tr>
<tr>
<td></td>
<td>FOV, mm</td>
<td>20×20×7.5</td>
</tr>
<tr>
<td></td>
<td>Voxel size, mm</td>
<td>0.078125×0.078125×0.5</td>
</tr>
<tr>
<td></td>
<td>Slice thickness/gap</td>
<td>0.5/0</td>
</tr>
<tr>
<td>Coronal</td>
<td>TE, ms</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>TR, s</td>
<td>2.54</td>
</tr>
<tr>
<td></td>
<td>Matrix</td>
<td>256×256</td>
</tr>
<tr>
<td></td>
<td>FOV, mm</td>
<td>20×20×16</td>
</tr>
<tr>
<td></td>
<td>Voxel size, mm</td>
<td>0.078125×0.078125×0.5</td>
</tr>
<tr>
<td></td>
<td>Slice thickness/gap, mm</td>
<td>0.5/0</td>
</tr>
<tr>
<td>Sagittal*</td>
<td>TE, ms</td>
<td>39</td>
</tr>
<tr>
<td></td>
<td>TR, s</td>
<td>3.28</td>
</tr>
<tr>
<td></td>
<td>Matrix</td>
<td>144×192</td>
</tr>
<tr>
<td></td>
<td>FOV, mm</td>
<td>15×20×11</td>
</tr>
<tr>
<td></td>
<td>Voxel size, mm</td>
<td>0.104167×0.104167×0.5</td>
</tr>
<tr>
<td></td>
<td>Slice thickness, mm</td>
<td>0.5/0</td>
</tr>
</tbody>
</table>

*, image with a sagittal slice plane were only acquired at T0. MRI, magnetic resonance imaging; TE, echo time; TR, repetition time; FOV, field of view.